Posted by Michael Wonder on 28 Sep 2023
Amicus Therapeutics announces FDA approval and launch of new treatment for Pompe disease
28 September 2023 - Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) approved in ERT experienced adults.
Amicus Therapeutics today announced that the US FDA has approved Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules.
